S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Price Target & Analyst Ratings

$0.40
+0.01 (+2.57%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.39
$0.42
50-Day Range
N/A
52-Week Range
$0.38
$0.94
Volume
245,964 shs
Average Volume
532,624 shs
Market Capitalization
$86.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Matinas BioPharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$3.00
652.82% Upside
High Prediction$3.00
Average Prediction$3.00
Low Prediction$3.00
TypeCurrent
6/3/22 to 6/3/23
1 Month Ago
5/4/22 to 5/4/23
3 Months Ago
3/5/22 to 3/5/23
1 Year Ago
6/3/21 to 6/3/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$3.00$3.00$3.00$3.00
Predicted Upside652.82% Upside420.38% Upside420.38% Upside383.48% Upside
Get Matinas BioPharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.


MTNB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MTNB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Matinas BioPharma Stock vs. The Competition

TypeMatinas BioPharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside652.82% Upside1,264.10% Upside209.91% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/31/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$3.00+420.37%
6/23/2022Aegis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Weinstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 6/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MTNB Price Target - Frequently Asked Questions

What is Matinas BioPharma's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Matinas BioPharma stock is Buy based on the current 2 buy ratings for MTNB. The average twelve-month price prediction for Matinas BioPharma is $3.00 with a high price target of $3.00 and a low price target of $3.00. Learn more on MTNB's analyst rating history.

Do Wall Street analysts like Matinas BioPharma more than its competitors?

Analysts like Matinas BioPharma more than other Medical companies. The consensus rating score for Matinas BioPharma is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how MTNB compares to other companies.

Does Matinas BioPharma's stock price have much upside?

According to analysts, Matinas BioPharma's stock has a predicted upside of 420.38% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NYSEAMERICAN:MTNB) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -